Immix Biopharma Inc
NASDAQ:IMMX

Watchlist Manager
Immix Biopharma Inc Logo
Immix Biopharma Inc
NASDAQ:IMMX
Watchlist
Price: 2.34 USD 4% Market Closed
Market Cap: 64.9m USD

Relative Value

There is not enough data to reliably calculate the relative value of IMMX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IMMX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
6.9
vs History
vs Industry
Median 3Y
-3
Median 5Y
-2.9
Industry
23
Forward
-2.8
vs History
vs Industry
Median 3Y
-4.3
Median 5Y
-4.3
Industry
19.7
vs History
vs Industry
Median 3Y
-4.1
Median 5Y
-4.2
Industry
22.8
vs History
2
vs Industry
32
Median 3Y
2.5
Median 5Y
2.5
Industry
2.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.3
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-1.9
Industry
4.1
Forward
-2.3
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-1.9
Industry
4.1
Forward
-1.8
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-2.4
Industry
4.9
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-2.3
Industry
3.6
vs History
vs Industry
15
Median 3Y
13.5
Median 5Y
13.6
Industry
4.7

Multiples Across Competitors

IMMX Competitors Multiples
Immix Biopharma Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Immix Biopharma Inc
NASDAQ:IMMX
65.2m USD 0 -3.1 -2.3 -2.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 901 062 -165 879.6 -201 430.7 -199 132.1
US
Abbvie Inc
NYSE:ABBV
328.7B USD 5.7 79.1 15.1 22.3
US
Amgen Inc
NASDAQ:AMGN
155B USD 4.5 26.1 14.1 23.3
US
Gilead Sciences Inc
NASDAQ:GILD
137B USD 4.8 23 10 13.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.6B USD 10.2 -114.9 24.4 25.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 018.5 -515.1 -560.9 -545.9
AU
CSL Ltd
ASX:CSL
119.5B AUD 5.1 28.1 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
53B USD 3.8 11.8 10.4 11.7
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.6 -64.2 -57.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
39.7B USD 16.9 -147.2 -658.7 -330.1
P/S Multiple
Revenue Growth P/S to Growth
US
Immix Biopharma Inc
NASDAQ:IMMX
Average P/S: 3 490 315.1
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 901 062
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
2 018.5
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
3.8
5%
0.8
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.9
29%
0.6
P/E Multiple
Earnings Growth PEG
US
Immix Biopharma Inc
NASDAQ:IMMX
Average P/E: 33.6
Negative Multiple: -3.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 879.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
79.1
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -114.9 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -515.1 N/A N/A
AU
CSL Ltd
ASX:CSL
28.1
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
7%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -147.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Immix Biopharma Inc
NASDAQ:IMMX
Average EV/EBITDA: 15.2
Negative Multiple: -2.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 430.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.1
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.1
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.9 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.4
11%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -658.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Immix Biopharma Inc
NASDAQ:IMMX
Average EV/EBIT: 19.7
Negative Multiple: -2.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 132.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.3
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -545.9 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.7
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -330.1 N/A N/A